Immunoglobulin isotype knowledge and application to Fc engineering.

Area of Science:

• Biotechnology
• Immunology
• Drug Discovery

Background:

• Monoclonal antibodies are a rapidly expanding class of therapeutics.
• Most approved therapeutic antibodies are human IgG1, mediating immune effector functions.
• Other antibody isotypes and IgG subclasses possess diverse functionalities.

Purpose of the Study:

• To review antibody isotypes and subclasses for therapeutic potential.
• To explore exploiting functional diversity for improved drug safety and performance.
• To detail cross-isotype engineering for novel therapeutic platforms.

Main Methods:

• Review of existing literature on antibody isotypes and subclasses.
• Analysis of functional diversity across different antibody formats.
• Discussion of amino acid exchange ('cross-isotypes') for engineering.

Main Results:

• Human IgG1 antibodies elicit immune effector functions.
• Alternative isotypes and subclasses offer potential for enhanced stability and reduced adverse events.
• Engineering through cross-isotypes can enable dual-antigen engagement.

Conclusions:

• Diverse antibody isotypes and subclasses hold significant therapeutic promise.
• Cross-isotype engineering represents a novel strategy for developing advanced antibody therapeutics.
• Exploiting functional diversity can optimize antibody drug safety and clinical performance.